Abstract
Obesity is associated with poor cardiovascular outcomes independent of comorbid diabetes; inflammation is a proposed link. In overweight and obese individuals with diabetes, glucagon-like peptide 1 (GLP-1) receptor agonists improve markers of inflammation and cardiovascular risk. Whether this effect persists in individuals without diabetes is not known. We evaluated the effect of exenatide, a GLP-1 receptor agonist, on inflammation and cardiovascular risk factors compared to hypocaloric diet and placebo injections in overweight and obese women without diabetes who demonstrated early clinically significant weight loss.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
